Researchers provided genetic diagnoses for about 68 percent of their primary antibody deficiency cohort, which altered clinical management in about half of them.
Two research teams warn that CRISPR-based gene editing could boost cancer risk by affecting p53 function, according to Stat News.
The study found that resistant clones in triple-negative breast tumors existed prior to chemo, but transcriptional changes happened in response to therapy.
CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.
Researchers have increased their estimate of the heritability of ASD to 83 percent based on a reanalysis of their prior study of Swedish families.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
Investigators intend to genotype the biorepository using Illumina arrays with the aim of identifying markers that can be used to inform treatment and prevention efforts.
The team will use the new research grant to further develop the Stockholm3 prostate cancer test and to design follow-on diagnostics to help treat patients with the disease.
The researchers reported single-cell small-RNA profiling could have applications in studying tumor heterogeneity as well as for in vitro fertilization.
The researchers will use single-cell genomics and other approaches to generate information that could ultimately be used to diagnose, monitor, and treat disease.
Cancer researcher Alan Rabson has died at 92, the New York Times reports.
As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.
In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.
The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.